These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 29211316)

  • 21. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
    Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
    Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial.
    Pinsky PF; Parnes HL; Andriole G
    BJU Int; 2014 Feb; 113(2):254-9. PubMed ID: 24053621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
    Roobol MJ; Kerkhof M; Schröder FH; Cuzick J; Sasieni P; Hakama M; Stenman UH; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis L; Recker F; Berenguer A; Ruutu M; Kujala P; Bangma CH; Aus G; Tammela TL; Villers A; Rebillard X; Moss SM; de Koning HJ; Hugosson J; Auvinen A
    Eur Urol; 2009 Oct; 56(4):584-91. PubMed ID: 19660851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH; Hugosson J; Carlsson S; Tammela T; Määttänen L; Auvinen A; Kwiatkowski M; Recker F; Roobol MJ
    Eur Urol; 2012 Nov; 62(5):745-52. PubMed ID: 22704366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme.
    Boniol M; Boyle P; Autier P; Ruffion A; Perrin P
    BJU Int; 2012 Dec; 110(11):1648-52. PubMed ID: 22984785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Black A; Parnes HL; Grubb R; David Crawford E; Miller A; Reding D; Andriole G
    Cancer Epidemiol; 2012 Dec; 36(6):e401-6. PubMed ID: 23000116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening.
    Etzioni R; Gulati R; Cooperberg MR; Penson DM; Weiss NS; Thompson IM
    Med Care; 2013 Apr; 51(4):295-300. PubMed ID: 23269114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Luján M; Páez A; Pascual C; Angulo J; Miravalles E; Berenguer A
    Eur Urol; 2006 Dec; 50(6):1234-40; discussion 1239-40. PubMed ID: 16704893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Bokhorst LP; Bangma CH; van Leenders GJ; Lous JJ; Moss SM; Schröder FH; Roobol MJ
    Eur Urol; 2014 Feb; 65(2):329-36. PubMed ID: 23954085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lethal Prostate Cancer in the PLCO Cancer Screening Trial.
    Shoag J; Mittal S; Halpern JA; Scherr D; Hu JC; Barbieri CE
    Eur Urol; 2016 Jul; 70(1):2-5. PubMed ID: 27166670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen-based screening: controversy and guidelines.
    Kim EH; Andriole GL
    BMC Med; 2015 Mar; 13():61. PubMed ID: 25857320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer mortality in the Finnish randomized screening trial.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for prostate cancer: the current evidence and guidelines controversy.
    Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
    Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Haines IE; Gabor Miklos GL
    J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
    Roobol MJ; Kranse R; Bangma CH; van Leenders AG; Blijenberg BG; van Schaik RH; Kirkels WJ; Otto SJ; van der Kwast TH; de Koning HJ; Schröder FH;
    Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.
    Ilic D; Djulbegovic M; Jung JH; Hwang EC; Zhou Q; Cleves A; Agoritsas T; Dahm P
    BMJ; 2018 Sep; 362():k3519. PubMed ID: 30185521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
    J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PSA screening: determinants of primary-care physician practice patterns.
    Tasian GE; Cooperberg MR; Potter MB; Cowan JE; Greene KL; Carroll PR; Chan JM
    Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):189-94. PubMed ID: 22343837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.